Peanut Allergy
99
8
15
58
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
33 trials with published results (33%)
Research Maturity
58 completed trials (59% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
8.1%
8 terminated out of 99 trials
87.9%
+1.4% vs benchmark
15%
15 trials in Phase 3/4
57%
33 of 58 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 58 completed trials
Clinical Trials (99)
Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients
Efficacy of Tezepelumab in Peanut Oral Immunotherapy
Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
Food Oral Immunotherapy for Peanut Allergy
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy
Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
Using Commonly Available Food Products To Treat Food Allergy
Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children